For which types of bronchial cancer is stereotactic body radiotherapy (SBRT) indicated?

SBRT for Bronchial Cancer: Indications

SBRT (stereotactic body radiotherapy) is indicated for early-stage (stage I and selected node-negative stage IIA) non-small cell lung cancer (NSCLC) in medically inoperable patients or those who refuse surgery, and increasingly for oligometastatic disease. 1, 2

Primary Indications by Stage and Operability

Stage I NSCLC (T1-T2N0M0)

For medically inoperable patients:

• SBRT is the non-surgical treatment of choice 2
• Target dose: biologically equivalent tumor dose (BED10) of at least 100 Gy 2, 3
• Achieves local control rates of 85-98% 4
• Associated with low toxicity in elderly patients and those with COPD 2

For medically operable patients:

• Surgery remains the standard treatment 3
• SBRT should not be routinely offered unless patients refuse surgery 2, 3
• Three randomized trials comparing SBRT to surgery failed to complete accrual due to poor recruitment 2, 3
• A pooled analysis of STARS and ROSEL trials showed comparable 3-year recurrence-free survival, but evidence remains insufficient 2

Selected Node-Negative Stage IIA Disease

SBRT is recommended as primary treatment when patients are medically inoperable or refuse surgery 1

Tumor Location Considerations

Peripheral Tumors

• SBRT is highly effective with minimal toxicity 2
• Standard fractionation schemes can be used safely 5

Moderately Central Tumors

• Defined as tumors within 2 cm of mediastinal critical structures (bronchial tree, esophagus, heart, major vessels, spinal cord) 2
• SBRT using risk-adapted fractionation schemes achieves high local control with limited toxicity 2
• Requires dose adjustment: conventional or hypofractionated schedules recommended for tumors >5 cm or moderately central location 2

Ultracentral Tumors

• Defined as planning target volume overlapping trachea or main bronchi 2
• SBRT is NOT appropriate due to increased risk of severe toxicity 2
• Radical RT using hypofractionated schedules is the acceptable standard of care 2

Additional Indications

Oligometastatic Disease

• SBRT increasingly used for definitive local therapy to unifocal or oligometastases 1
• Particularly for lung metastases with controlled primary tumor 6

Postoperative Setting

• Indicated for positive pathological margins after resection 1

Critical Exclusions and Cautions

Contraindications:

• Ultracentral tumor location (overlapping trachea/main bronchi) 2
• Very limited life expectancy from comorbidities 3
• Severe interstitial lung disease or previously irradiated tissue 7

Require dose/fractionation adjustment:

• Large tumor volume (large PTV) 3
• Severe pulmonary comorbidity 3
• Central location 3

Key Advantages Over Surgery in Appropriate Patients

• No general anesthesia required 8
• Minimal recovery time 8
• Minimal impact on lung function 8
• Lower short-term morbidity and treatment-related death risk 8, 3
• Particularly beneficial for high-surgical-risk and elderly patients (≥80 years) 3

Important Caveats

Staging limitations: SBRT relies primarily on radiographic staging (CT/PET), which may result in understaging compared to surgical pathologic staging 8. This is less consequential in compromised patients with substantial comorbidities but more significant in good surgical candidates 8.

Tissue diagnosis: Many patients are treated based on radiographic characteristics without tissue diagnosis, risking inappropriate treatment of benign lesions 8.